Concentrated Insulins: Clinical Update of Therapeutic Options
The DOI matches its Crossref record; 66 of the 68 references it cites were found in a registry or an index.
Abstract
Improved glycemic control is associated with a reduced risk of diabetic complications. Optimal management of patients with type 2 diabetes includes nutritional therapy, physical activity and pharmacotherapy for glycemic control. Most patients with type 2 diabetes are initially managed with oral antidiabetic agents, but as β-cell function declines and the disease progresses, insulin therapy is frequently needed to maintain glycemic control. Insulin therapy given with multi-dose insulin injection regimen or by continuous insulin infusion is needed for patients with type 1 diabetes to achieve control. Obesity and its associated insulin resistance contribute to greater insulin requirements in patients with both type 1 and type 2 diabetes to achieve glycemic control, creating a need for concentrated insulin. Concentrated insulin formulations can be prescribed as an alternative to U100 insulin and provide the advantage of low injection volume, leading to less pain and possibly fewer insulin injections. This review includes a stepwise analysis of all currently available concentrated insulin products, analyzes the most up-to-date evidence, and presents this in combination with expert guidance and commentary in an effort to provide clinicians with a thorough overview of the characteristics and benefits of concentrated insulins in patients with type 1 and type 2 diabetes-instilling confidence when recommending, prescribing, and adjusting these medications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Long-acting GLP-1 RAs also reduce fasting glucose.1099”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1099]
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Self-citationOgden, C. L., Carroll, M. D., Lawman, H. G., Fryar, C. D., Kruszon-Moran, D., Kit, B. K., & Flegal, K. M. (2016) · JAMA · doi:10.1001/jama.2016.6361 · Cited by 2,178
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Self-citationUmpierrez, G. E., Hellman, R., Korytkowski, M. T., Kosiborod, M., Maynard, G. A., Montori, V. M., Seley, J. J., & Van den Berghe, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2098 · Cited by 1,126
Self-citationWhat causes the insulin resistance underlying obesity?
Hardy, O. T., Czech, M. P., & Corvera, S. (2012) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283514e13 · Cited by 563
Turner, R., Cull, C., Holman, R., & United Kingdom Prospective Diabetes Study Group (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00011 · Cited by 465
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402
Liu, L. L., Lawrence, J. M., Davis, C., Liese, A. D., Pettitt, D. J., Pihoker, C., Dabelea, D., Hamman, R., Waitzfelder, B., Kahn, H. S., et al. (2010) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00519.x · Cited by 402
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
Riddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. D. (2014) · Diabetes Care · doi:10.2337/dc14-0991 · Cited by 354
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Self-citationInsulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Molecular pathophysiology of hepatic glucose production
Sharabi, K., Tavares, C. D. J., Rines, A. K., & Puigserver, P. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.09.003 · Cited by 325
Garber, A. J., King, A. B., Prato, S. D., Sreenan, S., Balci, M. K., Muñoz-Torres, M., Rosenstock, J., Endahl, L. A., Francisco, A. M. O., & Hollander, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60205-0 · Cited by 325
Bolli, G. B., Riddle, M. C., Bergenstal, R. M., Ziemen, M., Sestakauskas, K., Goyeau, H., Home, P. D., & on behalf of the EDITION 3 study investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12438 · Cited by 301
Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-0990 · Cited by 274
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Meneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1668 · Cited by 226
Home, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc15-0249 · Cited by 221
Gut Microbiota, Endocrine-Disrupting Chemicals, and the Diabetes Epidemic
Velmurugan, G., Ramprasath, T., Mithieux, G., Swaminathan, K., & Ramasamy, S. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.05.001 · Cited by 174
Gough, S. C. L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., & Bergenstal, R. M. (2013) · Diabetes Care · doi:10.2337/dc12-2329 · Cited by 150
de la Peña, A., Riddle, M., Morrow, L. A., Jiang, H. H., Linnebjerg, H., Scott, A., Win, K. M., Hompesch, M., Mace, K. F., Jacobson, J. G., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0721 · Cited by 125
Clinical use of U-500 regular insulin: Review and meta-analysis
Reutrakul, S., Wroblewski, K., & Brown, R. L. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600229 · Cited by 94
Korsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89
Insulin management of type 2 diabetes mellitus.
Petznick, A. M. (2011) · PubMed · doi:10.1016/s0002-838x(11)60220-7 · Cited by 77
Treatment Approach to Patients With Severe Insulin Resistance
Church, T., & Haines, S. T. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.97 · Cited by 76
on behalf of the CONCLUDE Study Group, Philis-Tsimikas, A., Klonoff, D. C., Khunti, K., Bajaj, H. S., Leiter, L. A., Hansen, M. V., Troelsen, L. N., Ladelund, S., Heller, S., et al. (2020) · Diabetologia · doi:10.1007/s00125-019-05080-9 · Cited by 73
de la Peña, A., Seger, M., Soon, D., Scott, A. J., Reddy, S. R., Dobbins, M. A., Brown‐Augsburger, P., & Linnebjerg, H. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.221 · Cited by 67
Pettus, J., Roussel, R., Zhou, F. L., Bosnyák, Z., Westerbacka, J., Berria, R., Jiménez, J., Eliasson, B., HRAMIAK, I. M., Bailey, T. S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0568-8 · Cited by 67
Use of concentrated insulin human regular (U-500) for patients with diabetes
Segal, A. R., Brunner, J. E., Burch, F. T., & Jackson, J. A. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090554 · Cited by 60
Knee, T. S., Seidensticker, D. F., Walton, J. L., Solberg, L. M., & Lasseter, D. H. (2003) · Endocrine Practice · doi:10.4158/ep.9.3.181 · Cited by 59
Clinical approach to the patient with diabetes mellitus and very high insulin requirements
Ovalle, F. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.06.025 · Cited by 54
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.08.006 · Cited by 51
Pasquel, F. J., Lansang, M. C., Khowaja, A., Urrutia, M. A., Cardona, S., Albury, B., Galindo, R. J., Fayfman, M., Davis, G., Migdal, A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1940 · Cited by 45
Self-citationGrunberger, G., Bhargava, A., Ly, T., Zisser, H., Ilag, L. L., Malone, J., Fan, L., Zhang, S., & Johnson, J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13947 · Cited by 44
Bulchandani, D. G., Konrady, T., & Hamburg, M. S. (2007) · Endocrine Practice · doi:10.4158/ep.13.7.721 · Cited by 41
U300, a novel long-acting insulin formulation
Sutton, G. L., Minguet, J., Ferrero, C., & Bramlage, P. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.970633 · Cited by 40
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
Goldman, J., & White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015597915 · Cited by 36
Concentrated insulins in current clinical practice
Schloot, N. C., Hood, R. C., Corrigan, S. M., Panek, R. L., & Heise, T. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.12.007 · Cited by 35
Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus
Crasto, W., Jarvis, J., Hackett, E., Nayyar, V, McNally, P. G., Davies, M. J., & Lawrence, I. G. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.073379 · Cited by 34
Liu, W., Yang, X., & Huang, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8726046 · Cited by 32
Wysham, C., Hood, R. C., Warren, M. L., Wang, T., Morwick, T. M., & Jackson, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15959.or · Cited by 29
Eby, E. L., Curtis, B. H., Gelwicks, S., Hood, R. C., IDRIS, I. R., Peters, A. L., Bergenstal, R. M., & Jackson, J. A. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000074 · Cited by 23
U-500 regular insulin use in hospitalized patients
Tripathy, P. R., & Lansang, M. C. (2015) · Endocrine Practice · doi:10.4158/ep14151.or · Cited by 23
Concentrated insulins: History and critical reappraisal
Heinemann, L., Beals, J. M., Malone, J. K., Anderson, J., Jacobson, J. G., Sinha, V. P., & Corrigan, S. M. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12861 · Cited by 22
Pang, T., Bain, S. C., Black, R. N. A., Boyle, J. G., Elliott, J., Holcombe, A., Lee, K. C. S., Mulligan, C., Saunders, L., Yousseif, A., et al. (2019) · Diabetic Medicine · doi:10.1111/dme.13847 · Cited by 21
Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment
Fonseca, V. A., & Haggar, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.17 · Cited by 19
An Overview of Concentrated Insulin Products
Painter, N. A., & Sisson, E. M. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.136 · Cited by 17
Hurren, K. M., & O’Neill, J. L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1245722 · Cited by 13
Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
Ponzani, P., Berra, C., Lelio, A. D., Sindaco, P., Loreto, C. D., Reggiani, F., Lucisano, G., & Rossi, M. C. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0511-4 · Cited by 12
Paulus, A. O., Colburn, J. A., True, M. W., Beckman, D., Davis, R. P., Wardian, J., Graybill, S. D., Folaron, I., & Lewi, J. E. (2016) · Endocrine Practice · doi:10.4158/ep161355.or · Cited by 10
Concentrated Insulins: A Review and Recommendations.
Gonzalvo, J. D., Patel, D. K., & Olin, J. L. (2017) · Europe PMC (PubMed Central) · Cited by 8
Ponzani, P., Berra, C., Lelio, A. D., Sindaco, P., Loreto, C. D., Reggiani, F., Lucisano, G., & Rossi, M. C. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00722-y · Cited by 8
van Mark, G., Lanzinger, S., Sziegoleit, S., Putz, F. J., Durmaz, M., Borscheller, M., Danne, T., Seufert, J., Holl, R. W., & Bramlage, P. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00983-w · Cited by 7
Zhou, F. L., Nicholls, C. J., Xie, L., Wang, Y., Vaidya, N., & Meneghini, L. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.73 · Cited by 7
Kedia, R., Desouza, C., Smith, L., & Shivaswamy, V. (2017) · Journal of diabetes and its complications · doi:10.1016/j.jdiacomp.2017.02.008 · Cited by 6
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
Rendell, M. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s132581 · Cited by 3
Pasquel, F. J., Lansang, M. C., Khowaja, A. A., Urrutia, M. A., Cardona, S., Albury, B. S., Galindo, R. J., Fayfman, M., Davis, G. M., Migdal, A. L., et al. (2020) · doi:10.2337/dc20-1234/suppl.12016428 · Cited by 3
Self-citation
Cited by
Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study
Wang, L., Yu, W., Yin, X., Cui, L., Tang, S., Jiang, N., Cui, L., Zhao, N., Lin, Q., Chen, L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.21106 · Cited by 573
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationDeardorff, W. J., Cenzer, I. S., Nguyen, B., & Lee, S. J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.6745 · Cited by 146
Risk of Subsequent Fractures in Postmenopausal Women After Nontraumatic vs Traumatic Fractures
Crandall, C. J., Larson, J. C., LaCroix, A. Z., Robbins, J. A., Wactawski‐Wende, J., Johnson, K., Sattari, M., Stone, K. L., Weitlauf, J. C., Gure, T. R., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2617 · Cited by 73
Schacter, G. I., & Leslie, W. D. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.005 · Cited by 61
Metadata
- Authors
- Umpierrez, G. E., Holt, E. H., Einhorn, D., & McGill, J. B.
- Corresponding author
- Umpierrez, Guillermo E.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 26
- Issue
- Suppl 3
- Pages
- 1-11
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3019111156
- Cited by
- 44
- References
- 68
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 32 · 2020: 4
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK111024)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- insulin therapy, type 1 diabetes, type 2 diabetes, glycemic control, insulin resistance, obesity, continuous insulin infusion, insulin formulations
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.